Chenghao Chu - Concepedia

Author

Chenghao Chu

Indiana University – Purdue University Indianapolis ORCID

Also Known As

C. Chu, Cheng-Hao Chu, Chenghao Chu, Chu, Chenghao

Publications

736

Citations

H-Index

Concepts

All Affiliations

Indiana University – Purdue University Indianapolis Vertex Pharmaceuticals (United States)Indiana University School of Medicine Lurie Children's Hospital University of Colorado Denver

About

Chenghao Chu is an author at Indiana University – Purdue University Indianapolis specializing in medicine, extracellular matrix, and vascular biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	222
2	Public Health	2	2	95
3	Engineering	1	1	13
4	Social Sciences	1	1	26
5	Biomedical Engineering	1	1	13

Chenghao Chu

Publications

663

Citations

H-Index

Page 1

	Year	Citations
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> Allele Edith T. Zemanick, Jennifer L. Taylor‐Cousar, Jane C. Davies, American Journal of Respiratory and Critical Care Medicine	2021	261
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele Jennifer L. Goralski, Jordana E. Hoppe, Marcus Mall, American Journal of Respiratory and Critical Care Medicine	2023	113
A randomized controlled trial testing a virtual perspective-taking intervention to reduce race and socioeconomic status disparities in pain care Adam T. Hirsh, Megan Miller, Nicole A. Hollingshead, Pain Family MedicinePain TherapyHealth Care DisparityPain MedicineVirtual Perspective-taking Intervention	2019	68
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials Ahmet Uluer, Gordon MacGregor, Pilar Azevedo, The Lancet Respiratory Medicine MedicinePhase 2	2023	61
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ≥6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A Phase 3, Open-Label Clinical Trial Claire Wainwright, Susanna A. McColley, Paul McNally, American Journal of Respiratory and Critical Care Medicine	2023	57
Transgelin induces dysfunction of fetal endothelial colony-forming cells from gestational diabetic pregnancies Kaela M. Varberg, Rashell O. Garretson, Emily K. Blue, American Journal of Physiology-Cell Physiology Fetal MedicineGynecologyAngiogenesisFibroblast Growth FactorPublic Health	2018	27
Weighted log‐rank test for time‐to‐event data in immunotherapy trials with random delayed treatment effect and cure rate Shufang Liu, Chenghao Chu, Alan Rong Pharmaceutical Statistics Cancer ManagementClinical EndpointImmunologyTreatment EffectImmunotherapy	2018	27
Resveratrol improved the spatial learning and memory in subclinical hypothyroidism rat induced by hemi-thyroid electrocauterization Jin‐Fang Ge, Yayun Xu, Ning Li, Endocrine Journal NeuropsychologySpatial LearningSubclinical Hypothyroidism RatSocial SciencesOxidative Stress	2015	26
Kinetic analyses of vasculogenesis inform mechanistic studies Kaela M. Varberg, Seth Winfree, Chenghao Chu, American Journal of Physiology-Cell Physiology Ecfc DisplacementEngineeringKinetic AnalysesMechanotransductionBiomedical Engineering	2017	13
Development and Validation of a Composite Score for Excessive Alcohol Use Screening Wanzhu Tu, Chenghao Chu, Shanshan Li, Journal of Investigative Medicine	2016	10

Page 1